FLOWER MOUND, TX / ACCESSWIRE / May 16, 2022 / Black Bird Biotech, Inc. (OTC:BBBT), manufacturer of plant-based MiteXstream^TM biopesticide, today reported that a recent interview of President, Fabian Deneault, by PubCo Insight has been released.

Mr. Deneault's interview can be viewed here, as well as on social media: @BBBT_Corporate on Twitter; @BlackBirdBiotech on Instagram; and BlackBirdBiotech on Facebook, where viewers are able to join the BBBT Ambassador Group.

In this wide-ranging interview, Mr. Deneault discusses the company's continuing sales and marketing efforts around its MiteXstream^TM biopesticide, recent capital-raising efforts and the possibilities for BBBT in the future.

Also visit BBBT's corporate website, BlackBirdBiotech.com, for additional information about the company.

About BBBT

Black Bird Biotech is positioned to exploit market segments with powerful, re-imagined biotech products. Its EPA-registered biopesticide, MiteXstream^TM, eradicates mites and similar pests, including spider mites (a lethal pest in cannabis, grapes, hops, coffee, strawberries and many other agricultural crops), and eliminates molds and mildews. MiteXstream^TM is a pesticide, but it is not a poison - it's a pesticide re-imagined. The MiteXstream^TM Edge: use through the day of harvest without concern for residual 'pesticide' violations, including as it pertains to state cannabis testing. MiteXstream^TM is the foundational element of the company that carries vast potential worldwide as a highly effective, safe and extremely cost-effective replacement for many traditional 'poisonous' pesticides.

Forward Looking Statements:

This current press release contains 'forward-looking statements,' as that term is defined in Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future, including but not limited to, any products sold or cash flow from operations.

Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Contact:

Eric Newlan
Vice President
833-223-4204
eric@newlanpllc.com
BlackBirdBiotech.com

SOURCE: Black Bird Biotech, Inc.